reports
CanniMed Therapeutics Inc. Announces First Quarter Results
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (TSX:CMED) (“CanniMed” or the “Company”) today released its unaudited financial results of operations for the three months ended January 31, 2018. The information in this news release should be read in conjunction with the Company’s condensed consolidated interim financial statements and notes thereto (unaudited) for the three months ended January 31, 2018 and the Company’s audited consolidated financial statements and notes thereto for the year ended October 31, 20...
CanniMed Therapeutics Inc. Announces Quarterly Results Release Date
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (TSX:CMED) (“CanniMed” or the “Company”) announces that it plans to release its financial results for the three months ended January 31, 2018 before markets open on Monday, March 19, 2018. About CanniMed Therapeutics Inc. CanniMed is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 17 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-comp...
Changes to CanniMed Therapeutics Board Following Share Take-Up by Auro...
EDMONTON, Alberta & SASKATOON, Saskatchewan--(BUSINESS WIRE)-- Aurora Cannabis Inc. (“Aurora”) (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and CanniMed Therapeutics Inc. (“CanniMed”) (TSX: CMED) announced today that following the successful take up and payment of approximately 86.8% of the issued and outstanding of CanniMed Shares, three Aurora Cannabis appointees will join the CanniMed Board of Directors, effective immediately. The CanniMed Board of Directors will now be comprised of: Mr. John Knowles (L...
Aurora Cannabis Announces Success in Bid for CanniMed Therapeutics Thr...
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (“CanniMed”) (TSX: CMED) is advised that Aurora Cannabis Inc. (“Aurora”) has been successful in its offer (the “Offer”) for all issued and outstanding common shares of the Company. The information set out in this press release is based on information provided by Aurora. The number of CanniMed common shares (the “CanniMed Shares”) tendered as at the close of business on March 8, 2018 totals 17,847,341, representing approximately 70.66% of the total outstandi...
Aurora Cannabis Announces Receipt of Final Regulatory Approval for Can...
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (“CanniMed”) (TSX: CMED) today announced that Aurora Cannabis Inc. (“Aurora”) announced that it has received a No Action Letter from the Competition Bureau (Canada) regarding Aurora’s offer (the "Offer") to purchase all of the issued and outstanding common shares ("CanniMed Shares") of CanniMed that Aurora does not already own. This approval by the Competition Bureau (Canada) represents the final regulatory approval required before Aurora can begin its take-up of Ca...
CanniMed Medical Cannabis Topical Cream Provides Fast-Acting Relief to...
SASKATOON, Saskatchewan & WATERLOO, Ontario--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (TSX: CMED) (“CanniMed” or the “Company”) is pleased to announce that today the Company has started fulfilling orders and shipping CanniMed® Topical Cream Kits to registered patients. This innovative new product is a fusion of CanniMed’s industry-leading medical cannabis oil with Kalaya™ Carrier Base Gel, created by Avaria Health & Beauty Corp. (“Avaria”), one of Canada’s leading experts in the creation of advanced topical creams, gels, lotions a...
A director sold 236,700 shares at 33.398CAD and
A director at Cannimed Therapeutics Inc sold 236,700 shares at 33.398CAD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Aurora Cannabis and CanniMed Therapeutics File Offer Documents for Pre...
EDMONTON, Alberta & SASKATOON, Saskatchewan--(BUSINESS WIRE)-- Aurora Cannabis Inc. (“Aurora”) (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and CanniMed Therapeutics Inc. (“CanniMed”) (TSX: CMED) today announced the filing of Aurora’s Notice of Variation and CanniMed’s Notice of Change to Directors’ Circular (collectively the “Offer Documents”) in connection with Aurora’s improved offer to acquire all of the outstanding common shares of CanniMed (“CanniMed Shares”) not already owned by Aurora or its affiliates, described un...
CanniMed Therapeutics Inc. Announces 2017 Year End Financials Release ...
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (TSX:CMED) (“CanniMed” or the “Company”) announces that it plans to release its financial results for the year ended October 31, 2017 after close of markets on Monday, January 29, 2018. About CanniMed Therapeutics Inc. CanniMed is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 17 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-complia...
CanniMed Therapeutics Announces Continued Discussions with Aurora
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (“CanniMed” or the “Company”) (TSX:CMED) announces that it is continuing to discuss terms of a possible transaction with Aurora Cannabis Inc. (“Aurora”). Therefore, CanniMed and Aurora have each agreed to extend their previously announced standstill to expire at 5:00 pm (EST) today, and until such time (i) neither CanniMed nor Aurora will solicit any proxies of CanniMed shareholders, (ii) Aurora will not, directly or indirectly, acquire control or direction over any...
CanniMed Therapeutics Announces Continuation of Discussions with Auror...
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (“CanniMed” or the “Company”) (TSX:CMED) announces that it is continuing to discuss terms of a possible transaction with Aurora Cannabis Inc. (“Aurora”). Therefore, CanniMed and Aurora have each agreed to extend their previously announced standstill to expire at 5:00 pm (EST) today, and until such time (i) neither CanniMed nor Aurora will solicit any proxies of CanniMed shareholders, (ii) Aurora will not, directly or indirectly, acquire control or direction over any...
CanniMed Therapeutics Postpones Special Shareholders’ Meeting
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (“CanniMed” or the “Company”) (TSX:CMED) announces it has determined to postpone the Special Shareholders’ Meeting (the “Meeting”) originally scheduled for January 23, 2018 to Thursday, January 25 at 10:00 am (EST). The cut off time for the deposit of proxies will be at 10:00 am (EST) on Tuesday, January 23, 2018, being 48 hours prior to the time of the Meeting. Newstrike Resources Ltd. (“Newstrike”) has consented to such postponement. The Meeting will be held at th...
CanniMed Topical Cream – An Innovative New Way to Help Patients
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (TSX:CMED) (“CanniMed” or the “Company”) is pleased to announce the launch of CanniMed Topical Cream, an innovative new product that has been uniquely formulated to provide fast-acting relief from pain and inflammation. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180117005415/en/ CanniMed Topical Cream combines CanniMed's industry-leading cannabis oil with Kalaya Carrier Base Gel for effective and fast-acting relief...
CanniMed Therapeutics Inc. Announces Director Resignation
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (TSX: CMED) (“CanniMed” or the “Company”) announces that, effective January 15, 2018, Mr. Doug Banzet has resigned from the Company’s Board of Directors. About CanniMed Therapeutics Inc. CanniMed is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 17 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-compliant production process and world class ...
CanniMed Therapeutics Inc. Launches $725 Million Lawsuit Alleging Mult...
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (TSX: CMED) (“CanniMed”) today filed a lawsuit in the Ontario Superior Court of Justice alleging breach of confidentiality, intentional interference with economic relations, conversion, breach of contract and other allegations pursuant to the Securities Act (Ontario). The lawsuit also alleges that Aurora Cannabis Inc. (“Aurora”), several large shareholders of CanniMed (Golden Opportunities Fund Inc., SaskWorks Venture Fund Inc., Apex Investment Limited Partnership a...
Leading Independent Proxy Advisor ISS Recommends CanniMed Shareholders...
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (TSX: CMED) (“CanniMed” or the “Company”) today announced that Institutional Shareholder Services Inc. (“ISS”), a leading independent proxy voting advisory firm, has recommended that CanniMed shareholders vote “FOR” the acquisition of Newstrike Resources. In reaching its recommendation that CanniMed shareholders vote “FOR” the acquisition of Newstrike Resources, ISS stated: “[CanniMed Shareholders should] vote FOR the proposed acquisition of Newstr...
CanniMed Therapeutics Inc. Announces Strategic International Cannabis ...
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (TSX: CMED) (“CanniMed” or the “Company”) is pleased to announce that it has entered into a global marketing and distribution agreement (the “Agreement”) with the leading global pharmaceutical compounding company Fagron NV of Rotterdam, The Netherlands (Euronext Brussels: FAGR and Euronext Amsterdam: FAGR). Under the Agreement, Fagron and CanniMed will work closely together in utilizing Fagron’s extensive infrastructure to supply CanniMed’s medicinal cannabis produc...
Media Advisory – CanniMed Therapeutics Inc. and Up Cannabis Inc. CEO...
SASKATOON, Saskatchewan & OAKVILLE, Ontario--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (TSX: CMED) (“CanniMed”) and Up Cannabis Inc. (wholly-owned licensed producer of Newstrike Resources Ltd. (TSX-V: HIP) (“Up Cannabis”) are pleased to be participating in the AltaCorp Capital Institutional Investor Conference on Wednesday, January 10th at the Shangri-La Hotel in Toronto. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180109005667/en/ Speakers: Brent Zettl, President and C...
CanniMed Therapeutics Inc. and Up Cannabis Inc. (Wholly-Owned Licensed...
SASKATOON, Saskatchewan & OAKVILLE, Ontario--(BUSINESS WIRE)-- CanniMed Therapeutics Inc. (TSX: CMED) (“CanniMed”) and Up Cannabis Inc. (wholly-owned licensed producer of Newstrike Resources Ltd. TSX-V: HIP) (“Up Cannabis”) applaud the Saskatchewan government on their announcement today to issue approximately 60 cannabis retail permits to private operators in the lead up to the adult-use recreational market. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180108006871/en/ ...
CanniMed Therapeutics Inc.’s US Subsidiary Applies for State of Mich...
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- CanniMed Therapeutics Inc., (TSX: CMED) (“CanniMed” or the “Company”), through its wholly owned subsidiary SubTerra LLC, has applied for State of Michigan licenses for the production and processing of medical cannabis. Further to the municipal approval received from Carp Lake Township, Michigan (see news release dated December 14, 2017), the Company has applied to the State of Michigan for a Class C Grower License (1,500 plants), as well as a Processor License. Upon receipt of the St...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.